Vibostolimab
- Generic Name
- Vibostolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2231305-30-7
- Unique Ingredient Identifier
- 5XO3JF0FEK
- Background
Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06395090
- Locations
- 🇺🇸
Children's Mercy Hospital ( Site 2024), Kansas City, Missouri, United States
🇺🇸Children's Hospital of Philadelphia (CHOP) ( Site 2021), Philadelphia, Pennsylvania, United States
🇨🇳National Taiwan University Hospital ( Site 2983), Taipei, Taiwan
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 315
- Registration Number
- NCT04305054
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute ( Site 2009), Los Angeles, California, United States
🇺🇸UCLA Hematology & Oncology ( Site 2004), Los Angeles, California, United States
🇺🇸Providence Saint John's Health Center ( Site 2010), Santa Monica, California, United States
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT04305041
- Locations
- 🇮🇱
Chaim Sheba Medical Center ( Site 1701), Ramat Gan, Israel
🇫🇷A.P.H. Paris, Hopital Saint Louis ( Site 1107), Paris, France
🇫🇷Hopital Saint Andre ( Site 1108), Bordeaux, Gironde, France
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
- Conditions
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT04303169
- Locations
- 🇮🇹
Istituto Europeo di Oncologia ( Site 3301), Milano, Italy
🇮🇹Policlinico Le Scotte - A.O. Senese ( Site 3377), Siena, Italy
🇺🇸The Angeles Clinic and Research Institute ( Site 3009), Los Angeles, California, United States
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT04165070
- Locations
- 🇺🇸
Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States
🇺🇸The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio, United States
🇺🇸Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.